Available Until 9/10/2024
View Cart

Oncology Pharmacy Specialty Home Study Syllabus for Recertification: Module 2A-B (Cert # L239239)

ACPE Numbers: Various – see listing below
Content Release Date: 09/13/2023
Expiration Dates: 09/10/2024
Activity Type: Application-based
CE Credits: 8 contact hours
Activity Fee: $160 (ASHP member); $215 (non-member) 

The Home Study Syllabus is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 2 online home study activities (see table below). Each activity is designed to assess the learners’ ability to analyze and apply peer-selected contemporary articles to practice. 

Learners will be required to review the content of the articles and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice. 

These activities are part of the ASHP and ACCP professional development program for BCOP recertification approved by the BPS. 

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

  

    

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in:

  • Hematopoietic Cell Transplantation
  • Prostate Cancer
  • Pancreatic Cancer
  • Breast Cancer
  • Chronic Leukemia
  • Gynecologic Malignancies
  • Lung Cancer

Board certified pharmacists are eligible to receive up to 8 contact hours of recertification credit for completing this module. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Activity

ACPE Number

Contact Hours (ACPE & BPS)

Assessment Pass Point

Home Study Syllabus Module 2A: Hematopoietic Cell Transplantation, Prostate Cancer, Pancreatic Cancer

0204-9999-23-980-H01-P

4.0

83%
Home Study Syllabus Module 2B: Breast Cancer, Chronic Leukemia, Gynecologic Malignancies, Lung Cancer

0204-9999-23-981-H01-P

4.0

75%

 

Home Study Syllabus Module 2A: Hematopoietic Cell Transplantation, Prostate Cancer, Pancreatic Cancer
ACPE #: 0204-9999-23-980-H01-P 

Broers AEC, de Jong CN, Bakunina K, et al. Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. Blood Adv. 2022; 6:3378-85. 

Learning Objectives:

  • Describe the study of posttransplant cyclophosphamide for graft-versus-host disease (GVHD) prevention in allogeneic hematopoietic cell transplant.
  • Develop recommendations for the use of posttransplant cyclophosphamide in allogeneic hematopoietic cell transplant for prevention of GVHD.
  • Select appropriate patients to receive posttransplant cyclophosphamide based on the results of the HOVON-96 trial.

Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022; 386:1132-42. 

Learning Objectives:

  • Describe the study of darolutamide, docetaxel, and androgen deprivation therapy (ADT) for the treatment of prostate cancer in patients with metastatic castrate-sensitive disease.
  • Select appropriate patients to receive darolutamide, docetaxel, and ADT based on the results of the ARASENS trial.
  • Develop recommendations for the use of darolutamide, docetaxel, and ADT in patients with metastatic castrate-sensitive prostate cancer. 

Tempero MA, Pelzer U, O’Reilly EM, et al. Adjuvant nab-paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: results from a randomized, open-label, phase III trial. J Clin Oncol. 2023; 41:2007-19. 

Learning Objectives:

  • Describe the APACT study of adjuvant nab-paclitaxel and gemcitabine for the treatment of resected pancreatic cancer.
  • Develop recommendations for the use of adjuvant nab-paclitaxel and gemcitabine for the treatment of resected pancreatic cancer.
  • Select appropriate patients to receive adjuvant nab-paclitaxel and gemcitabine for the treatment of resected pancreatic cancer based on the results of the APACT study.

 

Home Study Syllabus Module 2B: Breast Cancer, Chronic Leukemia, Gynecologic Malignancies, Lung Cancer
ACPE #: 0204-9999-23-981-H01-P 

Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022; 40:3246-56. 

Learning Objectives:

  • Describe the EMERALD study of elacestrant for metastatic hormone receptor-positive breast cancer.
  • Develop recommendations for the use of elacestrant in patients with metastatic hormone receptor-positive breast cancer.
  • Select appropriate patients to receive elacestrant based on the results of the EMERALD trial. 

Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023; 388:319-32. 

Learning Objectives:

  • Describe the ALPINE study of zanubrutinib versus ibrutinib for the treatment of relapsed or refractory chronic lymphocytic leukemia.
  • Develop recommendations for the use of zanubrutinib for the treatment of relapsed or refractory chronic lymphocytic leukemia. 

DiSilvestro P, Banerjee S, Colombo N, et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial. J Clin Oncol. 2023; 41:609-17. 

Learning Objectives:

  • Describe the study of olaparib as frontline maintenance therapy for ovarian cancer in patient with a BRCA mutation.
  • Develop recommendations for the use of olaparib as frontline maintenance therapy for ovarian cancer patients with a BRCA mutation.
  • Select appropriate patients to receive frontline maintenance olaparib based on the results of SOLO1. 

Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer (CheckMate 816). N Engl J Med. 2022; 386:1973-85. 

Learning Objectives:

  • Describe the CheckMate 816 trial of nivolumab plus chemotherapy for patients with resectable lung cancer.
  • Develop recommendations for the use of nivolumab plus chemotherapy in patients with resectable lung cancer based on the results of the CheckMate 816 trial.
  • Select appropriate patients to receive nivolumab plus chemotherapy based on the results of the CheckMate 816 trial. 

 

Full Faculty Bios

Courtney Cavalieri, PharmD, BCOP*
Clinical Oncology Pharmacist
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah

Brette Conliffe, PharmD, BCOP
Clinical Oncology Supervisor
University of Louisville Health/Brown Cancer Center
Louisville, Kentucky 

Karen Fancher, PharmD, BCOP*               
Associate Professor of Pharmacy Practice
Duquesne University School of Pharmacy
Pittsburgh, Pennsylvania
Clinical Pharmacy Specialist, Oncology
University of Pittsburgh Medical Center Passavant
Pittsburgh, Pennsylvania 

Lauren Ice, PharmD, BCOP, BCPS
Clinical Pharmacy Specialist
Corewell Health
Grand Rapids, Michigan 

Alexis Jones, PharmD, BCOP, CPP
Clinical Pharmacist, Gynecologic Oncology
University of North Carolina Medical Center
Chapel Hill, North Carolina

Janelle Mann, PharmD, BCOP
Manager of Clinical Pharmacy Services / Clinical Oncology Pharmacist
Alvin J. Siteman Cancer Center / Washington University School of Medicine
St. Louis, Missouri 

Anthony J. Perissinotti, PharmD, BCOP*
Hematology Clinical Pharmacist Specialist
University of Michigan
Ann Arbor, Michigan 

Danielle Roman, PharmD, BCOP              
Manager, Oncology Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, Pennsylvania 

Christine M. Walko, PharmD, BCOP, FCCP*
Senior Member, Individualized Cancer Management
Precision Medicine Team Lead
Moffitt Cancer Center
Tampa, Florida

*Content Matter Experts

Angela T. Cassano, PharmD, BCPS, FASHP
Sue Dombrowski, MS, RPh

David Awad, PharmD, BCOP
Mollie Beck, PharmD, BCOP
Denae Beckman, PharmD, BCOP
Miranda Benfield, PharmD, BCOP
Yuliya Byakina, PharmD, BCOP
Alexis Chapman, PharmD, BCOP
Nicholas Chow, PharmD, BCOP
Jonathan Crowley, PharmD, BCOP
Zhou Fang, PharmD, BCOP
Krystal Garrovillo Seigler, PharmD, BCPS, BCOP
Sara Gordon, PharmD, BCOP
Christina Gullion, PharmD, BCOP
Carolyn Hall, PharmD, BCOP
David W Harris, PharmD, BCOP
Susan Hauswirth, BSPharm, BCOP
Hailey Hill, PharmD, BCOP
Mikala Hillis, PharmD, BCOP
Jerline Hsin, PharmD, BCPS, BCOP
Christine Hughes, PharmD, BCOP, MBA
Mitchell Hughes, PharmD, BCOP
Raymond Iannuccillo, PharmD, MBA, BCPS, BCOP
Mark Jao, PharmD, BCOP
Elle Kim, RPh, BCPS, BCOP
Tiffany Knoll, PharmD, MS, BCOP
Lesli Lavery, PharmD, BCOP
Christopher Lee, PharmD, BCOP
Nicole Lees, PharmD, BCOP
Matthew Lei, PharmD, BCOP
Tammy Li, PharmD, BCOP
Pohung Lin, PharmD, BCPS, BCOP
Alyssa Loecher, PharmD, BCOP
Amanda Lucky, PharmD, BCPS, BCOP
Jessica Mack, PharmD, BCOP
Samantha Maples, PharmD, BCOP
Izabela Mazur, PharmD, BCOP
Conor McGladrigan, PharmD, JD, BCOP, BCSCP
William McSkimming, PharmD, BCOP
Katlyn Mulhall, PharmD, BCOP
Jeanne Noe, PharmD, BCOP
Danielle Otto, PharmD BCOP
Jeremy Pappacena, PharmD, BCOP
Marie Parish, PharmD, BCOP, BCPS
Christopher Pohland, PharmD, BCOP
Justine Preedit, PharmD, BCOP
Mohammad Rattu, PharmD, BCOP, BCPS, BCGP
Forrest Ridgway, PharmD, BCPS, BCOP
John Patrick Sanchez, PharmD, BCOP
Gianni Scappaticci, PharmD, BCOP
Michelle Schroeder, PharmD, BCOP
Ryan Schuller, PharmD, BCOP
Patrick Shin, PharmD, BCOP
Shayna Simon, PharmD, BCOP
Amanda Sirisaengtaksin, PharmD, BCOP
Christopher Smith, PharmD, BCOP
Stephanie Spitzer, PharmD, BCOP
Carol Stadler, RPh, Pharm.D., BCOP
Mellissa Taylor, PharmD, BCOP
Zane Waite, PharmD, BCOP
Jaelyn Wewtfield, PharmD, BCOP
Jamie Ziggas, PharmD, MS, BCOP
Colton Zwart, PharmD, BCOP

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

The following persons in control of this activity’s content have relevant financial relationships:

Anthony J. Perissinotti: Advisory Board, BeiGene, Janssen, and Abbvie 

All other persons in control of content do not have any relevant financial relationships with an ineligible company. 

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

  • Complete the attestation statement
  • Review all content
  • Complete and pass the assessments
  • Complete the evaluations

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

Development

ASHP collaborates with ACCP on oncology pharmacy activities.